ddC Coordinating Ctr
Wellesley Hills, Massachusetts, 021810003, United States
NCT Number: NCT00002081
To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection. To observe serious toxicities in this population.
Looking for future studies?
Notify Me1 day and older
All sexes
Interventional
Not applicable
Wellesley Hills, Massachusetts, 021810003, United States
Patients are treated with 1 of 2 doses of ddC administered orally (PO) in combination with AZT administered PO (patients who are unable to tolerate this dose of AZT may receive a lower dose).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Hoffmann-La Roche
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00000810
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Stanford, California, United States
View Trial DetailsNCT00000842
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsNCT00000782
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Palo Alto, California, United States
View Trial DetailsNCT00000739
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Long Beach, California, United States
View Trial Details